Glitazones in type 2 diabetes: An update

Drug and Therapeutics Bulletin

Volumn 46, Issue 4, 2008, Pages 25-29

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

COMPETACT; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; INSULIN; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; METFORMIN PLUS PIOGLITAZONE; METFORMIN PLUS ROSIGLITAZONE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA;

ADD ON THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DISEASE EXACERBATION; DRUG APPROVAL; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FLUID RETENTION; HEALTH CARE COST; HEART FAILURE; HEART INFARCTION; HUMAN; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOLYSIS; PATIENT COMPLIANCE; PERIPHERAL EDEMA; SIDE EFFECT; WEIGHT GAIN;

DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 44649103800     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.2008.03.0008     Document Type: Article

References (41)

1. Prescription Pricing Authority, 2007. Prescribing review - type 2 diabetes [online]. Available: http://www.ppa.org.uk/news/ pact-082007.htm [Accessed 27 March 2008].
2. Pioglitazone and rosiglitazone for diabetes. DTB 2001; 39: 65-8.
3. Avandia 4mg & 8mg film-coated tablets. Summary of product characteristics, UK. SmithKline Beecham plc, November 2007.
4. Actos tablets. Summary of product characteristics, UK. Takeda Global Research and Development Centre (Europe) Ltd, August 2007.
5. Stumvoll M, Häring HU. Glitazones: clinical effects and molecular mechanisms. Ann Med 2002; 34: 217-24.
6. Gastaldelli A et al. The effect of rosiglitazone on the liver: decreased gluconeogenesis in patients with type 2 diabetes. J Clin Endocrinol Metab 2006; 91: 806-12.
7. Smith U. Pioglitazone: mechanism of action. Int J Clin Pract 2001; suppl 121: 13-8.
8. Goldberg RB et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28: 1547-54.
9. Chiquette E et al. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004; 164: 2097-104.
10. Richter B et al. Pioglitazone for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD006060.DOI: 10.1002/14651858.CD006060.pub2. [Date of most recent substantive amendment 24 August 2006].
11. Perriello G et al. Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with type 2 diabetes. Diabet Med 2006; 23: 246-52.
12. Umpierrez G et al. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. Curr Med Res Opin 2006; 22: 751-9.
13. Aljabri K et al. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and mefformin in type 2 diabetes patients with poor glucose control: a prospective, randomised trial. Am J Med 2004; 116: 230-5.
14. Davidson JA et al. Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study. Diabetes Obes Metab 2006; 8: 164-74.
15. Richter B et al. Rosiglitazone for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No.: CD006063. DOI: 10.1002/14651858.CD006063.pub2. [Date of most recent substantive amendment 23 May 2007].
16. Rosenstock J et al. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 2006; 29: 554-9.
17. Avandamet 2mg and 4mg film-coated tablets. Summary of product characteristics, UK. SmithKline Beecham plc, June 2007.
18. Competact 15mg/850mg film-coated tablets. Summary of product characteristics, UK. Takeda Global Research and Development Centre (Europe) Ltd, October 2007.
19. Dormandy JA et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366:1279-89.
20. Erdmann E et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction. J Am Coll Cardiol 2007; 49: 1772-80.
21. Wilcox R et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke. Stroke 2007; 38: 865-73.
22. The DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368: 1096-105.
23. Kahn SE et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-43.
24. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007 14; 356: 2457-71.
25. Diamond GA et al. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 2007; 147: 578-81.
26. Home PD et al. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 2007; 357: 28-38.
27. Psaty BM, Furberg CD. The record on rosiglitazone and the risk of myocardial infarction. N Engl J Med 2007; 357: 67-9.
28. Singh S et al. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007; 298: 1189-95.
29. Lincoff AM et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298: 1180-8.
30. Lago RM et al. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007; 370: 1129-36.
31. European Medicines Agency, 2007. Questions and answers on the benefits and risks of rosiglitazone and pioglitazone [online]. London. Available: http://emea.europa.eu/pdfs/human/press/pr/ 48446407en.pdf [Accessed 27 March 2008].
32. European Medicines Agency, 2008. Press release: EMEA recommends new warnings and contraindications for rosiglitazone [online]. London. Available: http://www.emea.europa.eu/pdfs/human/press/pr/4223208en.pdf [Accessed 27 March 2008].
33. Medical and Healthcare products Regulatory Agency. Rosiglitazone and pioglitazone; cardiovascular safety. Drug Safety Update 2007; 1: 5-6.
34. GlaxoSmithKline, 2008. GlaxoSmithKline to revise Avandia (rosiglitazone maleate) label in Europe following assessment by CHMP [online]. Available: http://www.gsk.com/media/pressreleases/2008/ 2008∥esrelease_0033. html [Accessed 27 March 2008].
35. Food and Drug Administration, 2007. FDA adds boxed warning for heart-related risks to antidiabetes drug Avandia [online]. Available: http://www.fda.gov/bbs/topics/NEWS/2007/NEW01743.html [Accessed 27 March 2008].
36. Schwartz AV et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006; 91: 3349-54.
37. Takeda, 2007. Observation of an increased incidence of fractures in female patients who received long-term treatment with ACTOSO (pioglitazone HOI) tablets for type 2 diabetes mellitus [online]. Food and Drug Administration. Available: http://www.fda.gov/medwatch/ safety/2007/Actosmar0807.pdf [Accessed 27 March 2008].
38. Ryan EH et al. Diabetic macular edema associated with glitazone use. Retina 2006;26:562-70.
39. National Institute for Health and Clinical Excellence, 2003. Guidance on the use of glitazones for the treatment of type 2 diabetes [online]. Available: http://www.nice.org.uk/guidance/ index.jsp?action=byID&o=11502 [Accessed 27 March 2008].
40. National Institute for Health and Clinical Excellence, 2007. Type 2 diabetes (update): national clinical guideline for the management in primary and secondary care [online]. http://www.nice.org.uk/ nicemedia/pdf/T2DNICE-draftguidelinev7numberingcorrected.pdf [Accessed 27 March 2008].
41. Nathan DM et al. Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: update regarding the thiazolidinediones. Diabetologia 2008; 51: 8-11.